NASDAQ:XLO Xilio Therapeutics Q4 2025 Earnings Report $9.50 +0.01 (+0.11%) As of 01:20 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Xilio Therapeutics EPS ResultsActual EPS-$0.85Consensus EPS -$1.68Beat/MissBeat by +$0.83One Year Ago EPSN/AXilio Therapeutics Revenue ResultsActual Revenue$13.69 millionExpected Revenue$10.90 millionBeat/MissBeat by +$2.79 millionYoY Revenue GrowthN/AXilio Therapeutics Announcement DetailsQuarterQ4 2025Date3/23/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsXilio Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Annual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K)Annual report Xilio Therapeutics Earnings HeadlinesXilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Up 58.8% in JulyAugust 18 at 2:22 AM | americanbankingnews.comXilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesAugust 12, 2026 | globenewswire.comGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent highs. Margins as high as 75 percent make this the most profitable stretch in their history. Yet junior gold miners, the prime buyout targets for these cash-rich majors, are still priced as if gold were stuck at 1800 dollars an ounce instead of today's levels. Analyst Garrett Goggin calls this the Golden Anomaly, a gap he says rarely lasts long once a gold bull market gets going.August 18 at 1:00 AM | Golden Portfolio (Ad)Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | markets.businessinsider.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal OfficerJune 29, 2026 | finanznachrichten.deSee More Xilio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email. Email Address About Xilio TherapeuticsXilio Therapeutics (NASDAQ:XLO) is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity. The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands. These candidates are designed to selectively accumulate in tumor tissues and activate local innate and adaptive immunity. Xilio has advanced multiple assets into early‐phase clinical studies, evaluating safety, pharmacokinetics and preliminary signals of anti‐tumor activity across various solid tumor types. The pipeline also includes additional preclinical programs that apply the same targeting and activation principles to other cytokine payloads. Founded in 2018 and headquartered in Cambridge, Massachusetts, Xilio Therapeutics has assembled a management team with deep experience in oncology drug development and biologics engineering. The company conducts its clinical trials primarily in the United States and Europe and collaborates with academic and industry partners to accelerate the translation of its pipeline candidates into potential cancer therapies. Xilio remains committed to advancing its modular cytokine platform to address unmet needs in immuno‐oncology.View Xilio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Home Depot Analysts See a Path to $375 and BeyondRTX Stock Gets a Radar Lock on a $23B Navy WinA Star Investor Just Trimmed Amazon—Here's What It meansFabrinet’s Sell-Off May Prove It Is One of AI’s Most Misunderstood StocksWendy’s Deal Buzz May Give Fast-Food Investors a New Reason to LookMichael Burry Is Betting Against Palantir Again—Should Investors Care?Uncle Sam’s Chip Trick: How the Government Built a Silicon Moat Upcoming Earnings Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
